Skip to content

Investigating the effectiveness of BTA

Investigating the effectiveness of BTA in male androgenic alopecia

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231231060578N1
Enrollment
15
Registered
2024-02-01
Start date
2024-01-21
Completion date
Unknown
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L64 Androgenic alopecia. Drug-induced androgenic alopecia

Interventions

Intervention group: Intervention group: BTA (500 U/ml, botulinum toxin A
Dyston) diluted with 3 ml of 0.9% normal saline. The scalp is anatomically defined with sterile iodophor and 30 injection target sites (located in the frontal muscle, temporal muscle, parotid muscle,

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Androgenic alopecia male patients between 18 and 45 years old Have not used topical, intralesional or systemic treatment for permanent hair or color during and 6 months before the study. Patient satisfaction AGA diagnosis based on Norwood Hamilton criteria grade 2 to 6 Patients with no history of treatment with drugs known to interfere with BTA in the past 6 months

Exclusion criteria

Exclusion criteria: Patients with severe diseases of internal organs, eyes or skin Botulinum toxin contraindications include hypersensitivity reactions Patients with neuromuscular disorders (such as Eaton Lambert and myasthenia gravis, etc.) Patients with injection site infection Patients taking aminoglycosides, anticholinergic drugs, muscle relaxants and calcium channel blockers Patients who use drugs such as aspirin, warfarin, steroids, oral retinoid, hormonal or cytotoxic drugs, patients who present with Köbner's phenomenon, thromboembolic manifestations Diseases of the neuromuscular system; Inflammation, infection, or unhealed sores on the skin around the injection site on the head

Design outcomes

Primary

MeasureTime frame
From hair count statistics and objective score of head photos. Timepoint: Before and after study. Method of measurement: Professional photography camera and tripod (to ensure the same angle and distance for taking pictures) and taking pictures from fixed locations.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Khodabakhshian

Mashhad University of Medical Sciences

zoha1996.sh@gmail.com+98 51 3802 2826

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026